En español
NIDA

Clinical Research Grants Branch (CRGB)

What We Do:

The CRGB plans and supports extramural research grants to test medications for the treatment of drug abuse and dependence disorders in several key areas: controlled compound assessment clinical pharmacology studies, controlled clinical trials for new treatment agents or new indications for marketed medications and clinical studies of the pharmacological effects and interactions among experimental addiction medications and medications for associated medical conditions and psychotherapeutic agents. The Branch also supports experimental pharmacotherapy studies to enhance the efficacy of approved marketed medications, and experimental pharmacotherapy studies of psychotropic or other medications used in the treatment of mental disorders in drug dependent individuals including drug-induced or drug-related mental disorders. CRGB staff members provide technical assistance to grantees, contractors, and applicants. The CRGB provides guidance is given to investigators and manages the administrative aspects of DTMC's research and development contract portfolio.

Staff Biographies and Research Interests:

  • Kevin Walton, Ph.D., - Acting Branch Chief
    301-435-0762
    Program Official for clinical trial grants evaluating new therapeutics for smoking cessation and other drug dependence and use disorders.  Especially interested in repurposing of therapeutics.  Previous experience includes Scientific Review Officer for preclinical translational studies and 15 years in biopharmaceutical preclinical research for neurodegenerative and psychotherapeutic indications.  Joined NIDA in 2013.
  • Will M. Aklin, Ph.D., - Health Science Administrator
    301-443-3207
    Director of the Behavioral Therapy Development Program, involving Stage I (treatment generation, refinement), II (efficacy) and III (efficacy in real-world settings) treatment research. Interested in research to examine theory-derived treatment targets and mechanisms of behavior change, adherence, and studies that integrate behavioral/pharmacological treatment. Extensive clinical and research experience in behavioral and cognitive-behavioral treatment for substance dependence; adaptive brief interventions and adherence trials. Joined NIDA in 2008.
  • Ann Anderson, M.P.H., M.D., - Medical Officer
    301-435-0767
    A family practice physician for 12 years, including some obstetrics, then 3 yrs at CDC in fetal alcohol prevention and training to investigate disease clusters and outbreaks. Develops and oversees clinical trials for new pharmaceutical treatments for drugs of abuse. Serves as Program Officer for a portfolio of grants and cooperative agreements; reviews Data & Safety Monitoring Plans; evaluates progress.  Reported and analyzed adverse events, and published findings of multi-site trials for the Division. Joined DTMC in 1999.
  • Aidan Hampson, Ph.D., - Health Science Administrator
    301-443-8039
    Program Official and Scientific Officer for clinical trial grants evaluating new therapies for Opiate, Methamphetamine and Cannabis use disorders. Interested in improving tools available to clinical trial researchers. Previously was Scientific Review Officer for SBIR/STTR awards. Prior to that spent eight years in industrial preclinical drug development, six years as an academic cannabinoid researcher and four years in pharmacokinetics, drug metabolism and distribution. Joined NIDA in 2011.

This page was last updated February 2016